Download PDF
CC BY-NC-ND 4.0 · Avicenna J Med 2020; 10(02): 83-88
DOI: 10.4103/ajm.ajm_177_19
Case Report

Xanthoma disseminatum with extensive respiratory involvement effectively treated with cladribine: a case report

Heba Al-Tarcheh
Department of pulmonary medicine, Al Assad University Hospital, Damascus, Syria
,
Shahed Tish
Department of General Surgery, Washington University in Saint Louis, Saint Louis, Missouri
Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland, Ohio
,
Salloum Salloum
Department of pulmonary medicine, Al Assad University Hospital, Damascus, Syria
,
Ahed Haj Ibrahim
Department of pulmonary medicine, Al Assad University Hospital, Damascus, Syria
› Author Affiliations
Subject Editor: Financial support and sponsorship Nil.
› Further Information
   Permissions and Reprints

Abstract

Xanthoma disseminatum (XD) is a rare and benign proliferative systemic disease that usually affects the skin and mucosal membranes with variable extent. Extensive systemic involvement can be associated with higher morbidity. There is paucity in the literature describing this rare pathological entity, and the ideal management remains controversial. In this article, we report our experience with cladribine in treating a case of XD. We documented the clinical and pathological manifestations of a 24-year-old woman who was initially diagnosed with rheumatoid arthritis. She presented to our institute with respiratory compromise and was found to have XD affecting skin, mucosal membranes, joints, and bone marrow. The patient received six cycles of cladribine for 6 months, during which she showed a remarkable response in relation to the respiratory lesions. Her hemoglobin also normalized and inflammatory markers gradually decreased to reach normal values. However, her skin lesions did not respond to treatment but no new lesions appeared. With our experience with cladribine, we believe that it could be a promising treatment option for XD. However, more work has to be conducted to determine the efficacy and safety in the long term.

Key message: Given the rarity of this understudied entity, the natural history and the ultimate treatment remain unclear. We highlight the natural history and clinical course of xanthoma disseminatum (XD) in this article. We also describe our experience with cladribine in treating XD. We believe that similar experiences should be compiled to better understand this pathology and the effective therapy options for these patients.

Keywords

Cladribine - histiocytosis - non-Langerhans


Publication History

Article published online:
04 August 2021

© 2020. Syrian American Medical Society. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 Oka M, Oniki S, Komatsu M, Ikeda T, Matsuo M, Miyamoto Y. et al. Xanthoma disseminatum with intracranial involvement: Case report and literature review. Int J Dermatol 2010; 49: 193-9
    CrossrefPubMedGoogle Scholar
  • 2 Montgomery H, Osterberg AE. Xanthomatosis: Correlation of clinical, histopathologic and chemical studies of cutaneous xanthoma. Arch Derm Syphilol 1938; 37: 373-402
    CrossrefGoogle Scholar
  • 3 Büyükavci M, Selimoglu A, Yildirim U, Ertekin V, Atasoy M. Xanthoma disseminatum with hepatic involvement in a child. Pediatr Dermatol 2005; 22: 550-3
    CrossrefPubMedGoogle Scholar
  • 4 Behera B, Malathi M, Thappa DM, Vamanshankar H, Parida PK, Gochhait D. Xanthoma disseminatum presenting with hoarseness. Iran J Otorhinolaryngol 2017; 29: 365-8
    PubMedGoogle Scholar
  • 5 Campero M, Campero S, Guerrero J, Aouba A, Castro A. Cerebral and cutaneous involvements of xanthoma disseminatum successfully treated with an interleukin-1 receptor antagonist: A case report and minireview. Dermatology 2016; 232: 171-6
    CrossrefPubMedGoogle Scholar
  • 6 Gupta P, Khandpur S, Vedi K, Singh MK, Walia R. Xanthoma disseminatum associated with inflammatory arthritis and synovitis—A rare association. Pediatr Dermatol 2015; 32: e1-4
    CrossrefPubMedGoogle Scholar
  • 7 Caputo R, Veraldi S, Grimalt R, Gianotti R, Tosti A, Varotti C. et al. The various clinical patterns of xanthoma disseminatum. Considerations on seven cases and review of the literature. Dermatology 1995; 190: 19-24
    CrossrefPubMedGoogle Scholar
  • 8 Ozçelik U, Doğru D, Akçören Z, Coşkun T, Kaya S, Göçmen A. Xanthoma disseminatum: A child with respiratory system involvement and bronchiectasis. Pediatr Pulmonol 2005; 39: 84-7
    CrossrefPubMedGoogle Scholar
  • 9 Weiss N, Keller C. Xanthoma disseminatum: A rare normolipemic xanthomatosis. Clin Investig 1993; 71: 233-8
    CrossrefPubMedGoogle Scholar
  • 10 Adışen E, Aladağ P, Özlem E, Gürer MA. Cladribine is a promising therapy for xanthoma disseminatum. Clin Exp Dermatol 2017; 42: 717-9
    CrossrefPubMedGoogle Scholar
  • 11 Khezri F, Gibson LE, Tefferi A. Xanthoma disseminatum: Effective therapy with 2-chlorodeoxyadenosine in a case series. Arch Dermatol 2011; 147: 459-64
    CrossrefPubMedGoogle Scholar